Journal article · 2025 · Open access

Engineered apoptotic vesicle mimetics with tunable “eat-me” signaling precisely regulate tumor-associated macrophages for potentiating cancer immunotherapy

Yu Liu, Chunbai Xiang, Yeneng Dai, Chao Li, Michael Ngozi Okeke, Ting Jiang, Xing Wei Yang, Yehuda G. Assaraf, Kai Miao, Yue Wang, Zhiwei Zhang, Duo Zhang and 3 more

Acta Pharmaceutica Sinica B, 16(4), 2498–2512 · Published 29 November 2025 · DOI 10.1016/j.apsb.2025.11.032

Open full textCite this paper

In brief

“Engineered apoptotic vesicle mimetics with tunable “eat-me” signaling precisely regulate tumor-associated macrophages for potentiating cancer immunotherapy” is a 2025 journal article by Yu Liu and 14 co-authors, published in Acta Pharmaceutica Sinica B. OpenAlex counts 3 citations as of 18 November 2026, which puts it in the top 4% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Acta Pharmaceutica Sinica B.

Citations
3
Most cited in
2026 (3)
Field-weighted impact
0.89
References
54
Authors
15

Abstract

Repolarizing immunosuppressive M2-phenotype tumor-associated macrophages (TAMs) and blocking the CD47/SIRP α axis are promising strategies to enhance cancer immunotherapy. However, non-selective disruption of macrophage phenotypic balance and CD47/SIRP α signaling can lead to immune-related side effects. To address this, we develop a smart biomimetic nanoparticle (PARM) loaded with R848 and manganese ions (Mn 2+ ). PARM is coated with an apoptotic vesicle membrane and a pH-sensitive PEG corona, enabling targeted delivery to TAMs in the acidic tumor microenvironment (TME). The PEG corona protects the nanoparticle from uptake during circulation and sheds in the TME, exposing the apoptotic vesicle membrane. This triggers specific recognition and uptake by TAMs via the “eat-me” signal. R848 and Mn 2+ repolarize TAMs into a pro-inflammatory phenotype, while the activation of cGAS–STING pathway by Mn 2+ reduces SIRP α expression and enhances TAM phagocytosis. In vivo studies demonstrate that PARM remodels the immunosuppressive TME by repolarizing TAMs and promoting CD8 + T cell infiltration. This leads to significant inhibition of tumor growth and metastasis. These findings highlight the multifaceted role of the cGAS–STING pathway in TAM modulation and present a novel strategy for enhancing macrophage-based cancer immunotherapy. This study constructed a pH-responsive sheddable PEG-shielded apoptotic vesicle-biomimetic R848/Mn 2+ coordination nanoparticle termed PARM. PARM significantly inhibited tumor growth and metastasis by remodeling the immunosuppressed tumor microenvironment.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Liu, Y., Xiang, C., Dai, Y., Li, C., Okeke, M. N., Jiang, T., Yang, X. W., Assaraf, Y. G., Miao, K., Wang, Y., Zhang, Z., Zhang, D., Li, Y., Gong, P., & Zhao, Q. (2025). Engineered apoptotic vesicle mimetics with tunable “eat-me” signaling precisely regulate tumor-associated macrophages for potentiating cancer immunotherapy. Acta Pharmaceutica Sinica B, 16(4), 2498–2512. https://doi.org/10.1016/j.apsb.2025.11.032

MLA 9

Liu, Yu, et al. “Engineered apoptotic vesicle mimetics with tunable “eat-me” signaling precisely regulate tumor-associated macrophages for potentiating cancer immunotherapy.” Acta Pharmaceutica Sinica B, vol. 16, no. 4, 2025, pp. 2498–2512. https://doi.org/10.1016/j.apsb.2025.11.032.

Chicago

Liu, Yu, Chunbai Xiang, Yeneng Dai, Chao Li, Michael Ngozi Okeke, Ting Jiang, Xing Wei Yang, et al. 2025. “Engineered apoptotic vesicle mimetics with tunable “eat-me” signaling precisely regulate tumor-associated macrophages for potentiating cancer immunotherapy.” Acta Pharmaceutica Sinica B 16 (4): 2498–2512. https://doi.org/10.1016/j.apsb.2025.11.032.

Harvard

Liu, Y. et al. (2025) ‘Engineered apoptotic vesicle mimetics with tunable “eat-me” signaling precisely regulate tumor-associated macrophages for potentiating cancer immunotherapy’, Acta Pharmaceutica Sinica B, 16(4), pp. 2498–2512. doi:10.1016/j.apsb.2025.11.032.

IEEE

Y. Liu et al., “Engineered apoptotic vesicle mimetics with tunable “eat-me” signaling precisely regulate tumor-associated macrophages for potentiating cancer immunotherapy,” Acta Pharmaceutica Sinica B, vol. 16, no. 4, pp. 2498–2512, 2025, doi: 10.1016/j.apsb.2025.11.032.

BibTeX

@article{liu2025engineered,
  title     = {{Engineered apoptotic vesicle mimetics with tunable “eat-me” signaling precisely regulate tumor-associated macrophages for potentiating cancer immunotherapy}},
  author    = {Liu, Yu and Xiang, Chunbai and Dai, Yeneng and Li, Chao and Okeke, Michael Ngozi and Jiang, Ting and Yang, Xing Wei and Assaraf, Yehuda G. and Miao, Kai and Wang, Yue and Zhang, Zhiwei and Zhang, Duo and Li, Yaping and Gong, Ping and Zhao, Qi},
  journal   = {Acta Pharmaceutica Sinica B},
  year      = {2025},
  volume    = {16},
  number    = {4},
  pages     = {2498--2512},
  doi       = {10.1016/j.apsb.2025.11.032},
  url       = {https://doi.org/10.1016/j.apsb.2025.11.032}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer

  • tumor-associated macrophages
  • CD47-SIRPα axis
  • biomimetic nanoparticles
  • R848
  • manganese ions
  • cGAS-STING pathway
  • tumor microenvironment
  • cancer immunotherapy

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Liu, Y., Xiang, C., Dai, Y., Li, C., Okeke, M. N., Jiang, T., Yang, X. W., Assaraf, Y. G., Miao, K., Wang, Y., Zhang, Z., Zhang, D., Li, Y., Gong, P., & Zhao, Q. (2025). Engineered apoptotic vesicle mimetics with tunable “eat-me” signaling precisely regulate tumor-associated macrophages for potentiating cancer immunotherapy. Acta Pharmaceutica Sinica B, 16(4), 2498–2512. https://doi.org/10.1016/j.apsb.2025.11.032

How many times has this paper been cited?

3 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Acta Pharmaceutica Sinica B: sign in and open the full text from this page.

Who wrote this paper?

Yu Liu, Chunbai Xiang, Yeneng Dai, Chao Li, Michael Ngozi Okeke, Ting Jiang, Xing Wei Yang, Yehuda G. Assaraf, Kai Miao, Yue Wang, Zhiwei Zhang, Duo Zhang and 3 more.

What is the DOI of this paper?

10.1016/j.apsb.2025.11.032, permanently at https://doi.org/10.1016/j.apsb.2025.11.032. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.